'Baseline characteristics' presentation slideshows

Antiretroviral Therapy: A Case-Based Panel Discussion (Part I)

Antiretroviral Therapy: A Case-Based Panel Discussion (Part I). Michael S. Saag , MD Eric S. Daar , MD. From MS Saag , MD and ES Daar , MD at San Francisco, CA: March 29, 2013, IAS-USA. MERGED: 03-21-13. 30 yo white man Diagnosed on routine insurance examination

603 views • 45 slides

Clinical Appraisal of an Article on Prognosis

Clinical Appraisal of an Article on Prognosis. The Clinical Question. What is the risk of mortality among patients with hyperuricemia who received allupurinol ? PUBMED Search/Mesh Terms : Allopurinol Hyperuricemia Mortality Survival Advanced Search: Humans Males English.

317 views • 20 slides

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

Efficacy and Safety of the Anti-PD-1 <br />Monoclonal Antibody Pembrolizumab (MK-3475) in 411 Patients With Melanoma. Presented By Antoni Ribas at 2014 ASCO Annual Meeting. Disclosures. Presented By Antoni Ribas at 2014 ASCO Annual Meeting.

877 views • 20 slides

Immunologic and Virologic Disease Progression and Response to ART Across Geographic R egions:

Immunologic and Virologic Disease Progression and Response to ART Across Geographic R egions: Outcomes from HPTN 052. Mina C. Hosseinipour , MD, MPH Site Investigator UNC Project, Lilongwe, Malawi UNC School of Medicine, Chapel Hill, NC 6 th IAS Conference, Rome, Italy July 18, 2011.

316 views • 18 slides

Lancet 373:1765-72, 2009

Lancet 373:1765-72, 2009. Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose-lowering versus Standard Treatment. Kay et al, Lancet 373:1765-72, 2009.

350 views • 15 slides

Journal Club

271 views • 15 slides

266 views • 12 slides

Association between phenotypic resistance and virologic response to mega-HAART regimen in patients from the Frankfurt HI

Association between phenotypic resistance and virologic response to mega-HAART regimen in patients from the Frankfurt HIV Cohort. V Miller, A Cozzi-Lepri, K Hertogs, P Gute, B Larder, S Bloor, C Rottmann, AN Phillips, S Staszewski. Introduction.

264 views • 11 slides

Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II)

RABBIT II Trial. Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II). Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Barry F. Uretsky. RABBIT II Trial: Background.

841 views • 8 slides

TAXUS ATLAS Trial

298 views • 8 slides

Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II)

RABBIT II Trial. Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II). Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Barry F. Uretsky. RABBIT II Trial: Background.

310 views • 8 slides

Osman F, Saleh F, Corrigan M, Jackson T, Cil T. University of Toronto, Toronto, Canada

Increased Postoperative Complications in Bilateral Mastectomy Patients Compared to Unilateral M astectomy: An Analysis of NSQIP Database. Osman F, Saleh F, Corrigan M, Jackson T, Cil T. University of Toronto, Toronto, Canada. Introduction.

248 views • 8 slides

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

SESAMI Trial. Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial. Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Maurizio Menichelli. SESAMI Trial: Background.

391 views • 7 slides

Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER*

Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER*.

266 views • 7 slides

Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics

ISAR-SWEET Trial. Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics . Presented at American Heart Association Scientific Sessions 2004 Presented by Dr. Julinda Mehilli . ISAR-SWEET Trial.

167 views • 6 slides

Women's Health Study: Low-Dose Aspirin in Primary Prevention

Women's Health Study: Low-Dose Aspirin in Primary Prevention Trial. Women's Health Study: Low-Dose Aspirin in Primary Prevention. Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr. Paul M. Ridker.

412 views • 6 slides

Effects of PG-116800, a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial

PREMIER Trial. Effects of PG-116800, a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction. Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. W Douglas Weaver. PREMIER Trial.

199 views • 5 slides

Apixaban versus Aspirin in Atrial Fibrillation Patients ? 75 years old:

Apixaban versus Aspirin in Atrial Fibrillation Patients ? 75 years old: An Analysis from the AVERROES Trial Kuan H Ng, Olga O Shestakovska , John W. Eikelboom , Stuart J Connolly, Salim Yusuf, Robert G Hart

309 views • 1 slides

Abstract

121 views • 1 slides

Table 2. Mode of delivery ( N=276 )

119 views • 1 slides